I was just reaching out to try to get a patient enrolled in the Los Angeles area. I believe Ucla will be a site for this trial. But is not yet enrolling.
Considering we have nothing available, and the benefit that we've seen with oxervate on the regrowth of a sensory nerve, I'm hopeful the nasal spray can be a reasonable delivery.
I had a patient today, who had lost vision in his right eye many years ago, with a disc at risk (likely previous NAIOn). He awoke with inferior altitudinal vision loss in his left eye. When I checked his RAPD today, the right eye still maintains the APD despite florid swelling of the left optic nerve, And I'm curious that after the acute phase and swelling has disappeared, I hope that it does not reverse. I'm really curious in these patients who if the second eye is treated when NAION and the RAPD is less on the newly affected eye, would this drug delivery prevent the extent of apoptosis we would've seen without it?
B